Dr Jeremy Rees

Career

1. 1988

   Qualified in medicine

   University College and Middlesex Medical School, London, with distinctions in medicine, surgery and therapeutics.

2. Memorial Sloan Kettering, New York

   Part of his postgraduate training was spent at Memorial Sloan Kettering Cancer Center in New York.

3. 1999

   Consultant neurologist, Queen Square

   Appointed consultant neurologist at the National Hospital for Neurology and Neurosurgery and honorary senior lecturer in neuro-oncology.

4. Clinical lead, brain tumour unit

   Led the brain tumour unit at Queen Square and served as pathway director for brain cancer at London Cancer.

5. 2018

   NICE brain tumour guidelines

   Neurology expert member of the NICE committee that published the UK's national guidelines on the treatment of primary and secondary brain tumours.

6. Honorary Associate Professor, UCL

   Eight years as Honorary Associate Professor at University College London. He also practised as a consultant neurologist at Cleveland Clinic London.

7. Today

   Head of Neuro-Oncology, Shaare Zedek

   Now based in Jerusalem, leading neuro-oncology at Shaare Zedek Medical Center and seeing private patients in the hospital's Sharap unit.

Research and teaching

At Queen Square, Dr Rees led a research team investigating the role of multimodality imaging in the management of low-grade gliomas, the tumours at the centre of his clinical practice.

He has edited a textbook on neuro-oncology, written the chapters on intracranial tumours and paraneoplastic syndromes for the Oxford Textbook of Medicine, and has more than 80 publications.

He has run an educational course in neuro-oncology and lectures widely to doctors and other professional groups.

Selected publications

A selection of recent book chapters and papers.

Peer-reviewed papers

• Solomons M, Jaunmuktane Z, Weil RS, El Hassan T, Brandner S, Rees JH. Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better. Neuro-Oncology Practice 2020; 7: 196–201. Read the paper
• Dumas AA, Pomella N, Rosser G, et al. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. The EMBO Journal 2020. Read the paper
• Roberts TA, Hyare H, Agliardi G, et al. Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response. Scientific Reports 2020; 10: 9223. Read the paper
• Neill L, Rees JH, Roddie C. Neurotoxicity — CAR T-cell therapy: what the neurologist needs to know. Practical Neurology 2020. Read the paper
• Hyare H, Rice L, Thust S, et al. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status. European Journal of Radiology 2019. Read the paper
• Kosmin M, Solda F, Wilson E, Kitchen N, Rees J, Fersht N. The impact of route of diagnosis on survival in patients with glioblastoma. British Journal of Neurosurgery 2018; 32: 628–630. Read the paper
• Baumert B, Hegi M, van den Bent M, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology 2016; 17: 1522–1532.

Book chapters

• Neuro-oncology. Fersht N, McEvoy A, Rees JH. In: Clinical Neurology, 5th edn.
• Imaging of treatment response and pseudoresponse. Thust S, Hyare H, Rees JH. In: Glioblastoma: State-of-the-Art Clinical Neuroimaging. Nova, 2019.
• Intracranial tumours; Paraneoplastic neurological syndromes. Rees JH. In: Oxford Textbook of Medicine, 6th edn. Oxford, 2018.
• Drugs in neuro-oncology. Ledingham D, Rees JH. In: Drugs in Neurology. Oxford University Press, 2017.
• Neuro-oncology. Rees JH, Jäger HR, Fersht N, Brandner S, Bradford R, Wilson E. In: Queen Square Textbook of Neurology, 2nd edn. Blackwell, 2016.

Qualifications and registration